Barclays Maintains Overweight on Medline, Raises Price Target to $45
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $43 to $45.
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $43 to $45.
